1

Innovative Medicines Initiative

Graham HughesUK National Contact Point Health

"By joining the best academic teams with high-level industry scientists, IMI is building the research capacity needed to cure the major diseases of our time." Michel Goldman, IMI Executive Director

2

Innovative Medicines Initiative

3

IMI in the Health Theme

Activity 1:Biotechnology, generic tools & technologies for health

Activity 2:Translating research for

human health

Activity 3:Optimising the delivery of health care

cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues

Activity 4: Support actions & response to policy needs

The Innovative Medicines Initiative

4

Why is IMI needed?

5

What are the Expected Results?

• To modernise the development process of medicines; • To drive the development of innovative medicines with a

high level of safety and efficacy, for millions of patients; • To generate more and better quality jobs for scientists,

reversing the European brain drain; • To enhance European expertise and know-how in new

technologies to attract pharmaceutical R&D investment to Europe;

• To create a stronger competitive advantage for smaller companies (SMEs, spin-offs and start-ups) and public organisations by collaborating with a multitude of stakeholders.

6

How to Achieve Results

• Support “pre-competitive pharmaceutical research and development” – accelerate the development of safer and more effective medicines for patients

• Modernization of the drug development process, via new approaches, methods and technologies, better use of research results and data and more skilled staff

• Foster collaboration between stakeholders , e.g industry, academia, patient organisations, public authorities (inc regulators) , clinical centres etc

• Addresses the challenges in the development process of drugs rather than aiming to deliver new medicines

7

How is it funded?

EFPIA members fully fund their own participation and provide R&D resources such as staff, laboratories, materials and clinical research.

EU funds exclusively public organisations or nonprofit organisations and small and medium-sized enterprises (SMEs).

8

IMI Governance

Founding Members Overall Responsibility for operations of

IMI

Responsible for day to day management

15 Members Provide scientific advice to the board

Governing Board

Executive Director ( + staff)

Scientific CommitteeIMI J

oint

Und

erta

king

Stakeholder Forum

Annual meeting open to all stakeholders

Communication and Feedback

IMI States Representatives Group

One representative per MS or AS

Chair is observer on Governing Board

9

IMI Research Agenda

10

IMI Projects: Key facts

• Open and competitive calls with a peer review process by independent experts

• Average project size €15 - 20 million• Average consortium size in the range of:

- 9 – 16 pharmaceutical companies- 9 – 37 academic, SME, regulatory, patient organisations

• EU funding to academic, SME and other partners is– 75% of total eligible research costs– 100% of total eligible management and training costs

• Total eligible costs include direct eligible costs plus 20% overheads

11

IMI Research Consortium

12

IMI Call Process

Timeline

Grant and Project AgreementsFull Project Consortium

Involvement

EFPIA Consortium

Applicant Consortium

Applicant and EFPIA Consortium

Full Project Consortium

Full Project Proposal

2nd Peer Review

Evaluation Stage 2

Phase Activity

Expressions of Interest

1st Peer Review

Invitation to join for full Project Proposal

Evaluation Stage 1

Research Agenda

Annual Implementation Plan

Call with topics

Call Definition17 Nov 09

08 Feb 10

March 10

Q4 2010

13

1st Call (2008)

15 Projects

395 teams24 SMEs11 patient organisations

EU Budget = €281 Million

Pillars:• Drug Safety• Education and Training

Thematic Areas• Neurosciences• Diabetes• Lung Disease

UK SMEsCXR BiosciencesPsynova NeurotechSynairgen ReasearchChoice Pharma

14

2nd Call (2009)

Projects start March 2011

8 Projects

65EFPIA teams103 Academic teams23 SMEs2 patient organisations

EU Budget = €172 Million

Pillars:• Drug Efficacy• Knowledge Management

Thematic Areas• Cancer• Rheumatoid Arthritis• Infectious Disease

UK SMEsCyprotex DiscoveryMango Business SolutionsSimcyp LtdAssero LtdAcademic Concept Knowledge Ltd

15

3rd Call (2010)

Launched 22 Oct 2010EoI Deadline 18 Jan 2011Evaluations March/April

EU Budget = €114 Million

Pillars:• Drug Safety• Drug efficacy

• Education and Training

Thematic Areas• Inflammatory Disease• Neurological Disease

• Infectious Disease• Diabetes

16

4th Call

Technology Strategy BoardDriving Innovation

Launch Date 17th June 2011

18

Support

http://www.imi.europa.eu